SKINGENIXWEB.COM
Skingenix, Inc. | Dermal Regeneration TechnologiesDermal Regeneration Technologies
http://www.skingenixweb.com/
Dermal Regeneration Technologies
http://www.skingenixweb.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Wednesday
LOAD TIME
2.6 seconds
Domains By Proxy, LLC
Registration Private
Domain●●●●●●xy.com
14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309
Sco●●●ale , Arizona, 85260
UNITED STATES
View this contact
Domains By Proxy, LLC
Registration Private
Domain●●●●●●xy.com
14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309
Sco●●●ale , Arizona, 85260
UNITED STATES
View this contact
Domains By Proxy, LLC
Registration Private
Domain●●●●●●xy.com
14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309
Sco●●●ale , Arizona, 85260
UNITED STATES
View this contact
19
YEARS
0
MONTHS
29
DAYS
GODADDY.COM, LLC
WHOIS : whois.godaddy.com
REFERRED : http://registrar.godaddy.com
PAGES IN
THIS WEBSITE
7
SSL
EXTERNAL LINKS
5
SITE IP
50.63.98.1
LOAD TIME
2.625 sec
SCORE
6.2
Skingenix, Inc. | Dermal Regeneration Technologies | skingenixweb.com Reviews
https://skingenixweb.com
Dermal Regeneration Technologies
skingenixweb.com
Careers | Skingenix, Inc.
http://www.skingenixweb.com/careers
Skingenix, Inc. is committed to equal employment opportunity in its business operations and employment practices. The Company strives to comply with all applicable laws prohibiting discrimination against any applicant or employee on grounds of race, ancestry, place of origin, color, ethnic origin, citizenship, age, creed, sex, marital status, family status, handicap, record of offenses, and sexual orientation.
About US | Skingenix, Inc.
http://www.skingenixweb.com/about-us
Worldwide recognition and application of organ in situ regeneration in pursuit for the realization of the best quality of health management, longer lifespan, and a secured future. The Company is dedicated to achieve this vision by combining its earned proprietary technologies and formulation of essential polymolecular products for an excellent health.
Skingenix, Inc. announces successful completion of a Phase II, Randomized, Controlled, Multi-Center Study | Skingenix, Inc.
http://www.skingenixweb.com/uncategorized/2013/12/30/skingenix-inc-announces-successful-completion-of-a-phase-ii-randomized-controlled-multi-center-study
Skingenix, Inc. announces successful completion of a Phase II, Randomized, Controlled, Multi-Center Study. Skingenix, Inc. announces successful completion of a Phase II, Randomized, Controlled, Multi-Center Study to assess the Safety and Efficacy of their investigational product in patients with Diabetic Foot Ulcers. This clinical study was completed in December 2013 , more information can be found at www.clinicaltrials.gov. This entry was posted in Uncategorized. December 30, 2013.
Skingenix, Inc. announces completion of two pilot clinical studies with the investigational product in patients with Venous Leg Ulcers and Diabetic Foot Ulcers in USA. | Skingenix, Inc.
http://www.skingenixweb.com/uncategorized/2011/12/30/skingenix-inc-announces-completion-of-two-pilot-clinical-studies-with-the-investigational-product-in-patients-with-venous-leg-ulcers-and-diabetic-foot-ulcers-in-usa
Skingenix, Inc. announces completion of two pilot clinical studies with the investigational product in patients with Venous Leg Ulcers and Diabetic Foot Ulcers in USA. Under an Investigational New Drug Application (IND), Skingenix has successfully completed two pilot clinical studies in USA :. First clinical study was conducted in patients with Venous Leg Ulcer. The second clinical study was conducted in patients with Diabetic Foot Ulcers. These studies were completed in December 2011. December 30, 2011.
NEWS and MEDIA | Skingenix, Inc.
http://www.skingenixweb.com/news-media
Skingenix, Inc. announces successful completion of a Phase II, Randomized, Controlled, Multi-Center Study. Skingenix, Inc. announces successful completion of a Phase II, Randomized, Controlled, Multi-Center Study to assess the Safety and Efficacy of their investigational product in patients with Diabetic Foot Ulcers. This clinical study was completed in December 2013 , more information can be found at www.clinicaltrials.gov. Under an Investigational New Drug Application (IND), Skingenix has successfully ...
TOTAL PAGES IN THIS WEBSITE
7
Introduction[mebo]
http://en.mebo.com/Corporate/ShowInfo.asp?InfoID=7
MEBO Entities and Affiliates. Summary of Science and Technology. Core Science and Technology of MEBO. Exploration of Fundamental Mechanisms of Adult Human Body Regeneration. Eradication of Cancer Cells via Regeneration. Regeneration of Gastro- Intestinal Tract. Restoration of Aged Skin of Adult Humans. Systemic Regeneration of Aging High Mammals. How to Be Our Distributor. Published Papers and Reports. MEBO Scientific Breaking News. 8226;MEBO International, Inc. (California, U.S.A.). 8226; Skingenix, Inc.
MEBO India-MEBO India
http://www.mebo.co.in/index.php
MEBO’s products have been marketed in more than 70 countries, including New Zealand, Singapore, Russia, South Korea, Philippines, Thailand, Malaysia, United Arad Emirates, Egypt, Saudi Arabia, Kuwait and South America etc. Our mission is to apply Human Body Regenerative Restoration Science and to use the advanced regenerative technology and high-quality products to benefit the whole mankind. DR RONGXIANG XU RECEIVES THE PRESTIGIOU. DR RONGXIANG XU RECEIVES THE PRESTIGIOU. Mail: info@mebo.co.in.
MEBO Group
http://en.mebo.com/index.asp
MEBO Entities and Affiliates. Summary of Science and Technology. Core Science and Technology of MEBO. Exploration of Fundamental Mechanisms of Adult Human Body Regeneration. Eradication of Cancer Cells via Regeneration. Published Papers and Reports. Regeneration of Gastro- Intestinal Tract. Restoration of Aged Skin of Adult Humans. Systemic Regeneration of Aging High Mammals. How to Be Our Distributor. Published Papers and Reports. MEBO Scientific Breaking News. The patient has many sites of scar since c...
TOTAL LINKS TO THIS WEBSITE
5
Skytech Ingenieria
Camaras de Seguridad (CCTV). Detección y Extinción de Incendios. Conectividad y Acceso Lan/Wan. Soluciones de Voz, Fax, video y Datos/redes. Cableado Estructurado(Voz,Datos,Video). Redes Eléctricas y UPS.
Index of /
Skingeniusadvance.com
Skingeniusbeauty.com
Skingeniuspro.com
Skingenix, Inc. | Dermal Regeneration Technologies
Regenerative medicine and therapy is an innovative concept described through a new research field and represents a unique approach towards the goal of regenerating functional tissues and organs. The term regeneration implies that the human body can possibly be stimulated to regenerate by itself through the use of its own potential but this stimulation requires appropriate trigger or promotion factor as well as an appropriate physiological environment.
SKINGENLAB.COM - Generic Domain Registration - Marcaria.com
This domain has been registered through Marcaria.com.
Main Page - Bio.pe
10,000 Korean Human Genome Project. Ancient East Asian Genomes. Korean page: genomekorea.kr. Retrieved from " http:/ www.skingenomics.com/index.php/Main Page. Related Links [ Edit. This page was last modified on 26 January 2017, at 08:38. This page has been accessed 1,605,365 times. Content is available under BioLicense: the freest license.
SKINGENPHARMA.COM - Generic Domain Registration - Marcaria.com
This domain has been registered through Marcaria.com.
skingenuity.com - This website is for sale! - skingenuity Resources and Information.
The owner of skingenuity.com. Is offering it for sale for an asking price of 3900 EUR! This page provided to the domain owner free. By Sedo's Domain Parking. Disclaimer: Domain owner and Sedo maintain no relationship with third party advertisers. Reference to any specific service or trade mark is not controlled by Sedo or domain owner and does not constitute or imply its association, endorsement or recommendation.
Skingenx
Skingenx.com has been informing visitors about topics such as Facial Skin Care Products, localhost;id and ftplocate fsite cmd exec.nasl. Join thousands of satisfied visitors who discovered Folder name, Natural Anti Wrinkle and Organic Skin Care Reviews.